14
Participants
Start Date
June 30, 2008
Primary Completion Date
August 31, 2009
Study Completion Date
August 31, 2009
PX-12
Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
Cancer Centers of the Carolinas, Greenville
Tyler Cancer Center, Tyler
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale
Lead Sponsor
Cascadian Therapeutics Inc.
INDUSTRY